split-banner-image

DOMINO

Closed

ANZ 1301: DOMINO

BCT Study Chair:

Nicholas Zdenkowski

Neoadjuvant (pre-operative) systemic therapy is one of an increasing number of treatment options available for breast cancer. Patients may be asked to make complex decisions about their treatment at a time when they are dealing with the stress of their diagnosis. The ANZ1301 DOMINO study aims to find out if a Decision Aid developed to give women information about adjuvant and neoadjuvant treatment for breast cancer helps them make decisions about their treatment. The Decision Aid offers targeted information and a worksheet to clarify their views about the pros and cons of neoadjuvant therapy. Study participants will complete a series of online questionnaires over a 12 month period (computer and internet access is required).

international

0

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

59

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

5

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

DOMINO PUBLICATIONS

2019

Patient-reported outcomes with neoadjuvant vs adjuvant systemic therapy for operable breast cancer.

Zdenkowski N, Butow P, Spillane A, Douglas C, Snook K, Jones M, Oldmeadow C, Fewster S, Beckmore C, Boyle FM. The Breast. 2019; 4625-31, [DOI: 10.1016/j.breast.2019.04.003), Journal

2018

Exploring women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer.

Herrmann A, Boyle F, Butow P, Hall AE, Zdenkowski N. Health Science Reports. 2018; 1:e13 E-pub

Single-Arm Longitudinal Study to Evaluate a Decision Aid for Women Offered Neoadjuvant Systemic Therapy for Operable Breast Cancer.

Zdenkowski N, Butow P, Spillan A, Douglas C, Snook K, Jones M, Oldmeadow C, Fewster S, Beckmore C, Boyle FM, and for the Australia and New Zealand Breast Cancer Trials Group. Journal of the National Comprehensive Cancer Network 2018; 16(4):378-385, doi:10.6004/jnccn.2017.7063, Journal

2017

Patient reported outcomes according to receipt of neoadjuvant or adjuvant systemic therapy for breast cancer: results of a prospective longitudinal study.

Zdenkowski N, Butow P, Boyle FM on behalf of Australia and New Zealand Breast Cancer Trials Group. Controversies in Breast Cancer (CoBrCa) 2017; [OR06], Presentation

Primary results of a study to evaluate a decision aid for women offered neoadjuvant systemic therapy for breast cancer.

Zdenkowski N, Butow P, Spillane AJ, Douglas C, Beckmore C, Jones C, Boyle FM. Annals of Oncology 2017; 28(supp 5):[Poster 1431P], Poster

2016

A survey of Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer.

Zdenkowski N, Butow P, Mann GB, Fewster S, Beckmore C, Isaacs R, Douglas C, Boyle FM. Internal Medicine Journal. 2016; 46(6):677-683, Journal

LOAD MORE

Institutions